The Daily Byte
Breaking
Welcome to The Daily Byte — real stories from across Pakistan.
Saturday, 21 November 2026 · Pakistan

The Daily Byte

Stories from Pakistan that deserve to be heard
Minor Markets

AstraZeneca Klygefa wins EU and US approval

By The Daily Byte ·17 Nov 2026 ·3 min read
AstraZeneca's glass headquarters building in Cambridge, UK

AstraZeneca has won approval in the European Union and the United States for Klygefa, its rare disease treatment for adults with generalised myasthenia gravis, the UK drugmaker said on Monday 16 November 2026.

The approvals, announced by AstraZeneca's rare disease division Alexion, cover adults with generalised myasthenia gravis, known as gMG, who are anti-acetylcholine receptor antibody positive. The drug, also known by its scientific name gefurulimab, is given as a once-weekly injection under the skin that patients can administer themselves using an autoinjector.

First of its kind in both markets

AstraZeneca said Klygefa is the first and only approved dual-binding nanobody C5 inhibitor in both the EU and the US. The treatment works by blocking part of the immune system, known as complement C5, which attacks the connection between nerves and muscles in people with the condition.

Generalised myasthenia gravis is a rare autoimmune disorder that causes muscle weakness and fatigue. It can affect the muscles that control the eyes, face, swallowing, breathing and movement of the limbs, and symptoms can vary from day to day.

The European Commission granted approval following a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. In the US, the Food and Drug Administration approved the drug for the same group of patients.

Results from the PREVAIL trial

Both approvals were based on results from the PREVAIL Phase III trial, a global randomised, double-blind, placebo-controlled study. AstraZeneca said the trial met its main goal, showing a statistically significant and clinically meaningful improvement in patients' ability to carry out daily activities compared with placebo.

The company said improvements were seen as early as week one and were sustained through one year of treatment, and that the drug was generally well tolerated. Klygefa is already approved in Japan and other countries for certain adults with gMG, and regulatory submissions based on the PREVAIL results are under review in China and additional countries.

Second US approval on the same day

AstraZeneca also won a second US approval on Monday, for an expanded use of its immunotherapy Imfinzi in muscle-invasive bladder cancer. The Food and Drug Administration approved Imfinzi combined with enfortumab vedotin, a targeted therapy given before surgery, for patients who are ineligible for or have refused cisplatin-based chemotherapy.

The double approval gives the Cambridge-based company, one of the largest constituents of London's FTSE 100 index, fresh momentum in its rare disease and oncology businesses as it heads into the final weeks of the year. AstraZeneca's Alexion division, which it acquired in 2021, leads the company's work on rare diseases.

Source: AstraZeneca press release | Source: Reuters